Inventor profile of:

Daniel A. Gamache

City:

Arlington, Texas

Country:

United States

Published Applications:

49

Last publication date:

2019-01-31

Top Assignees for applications by Daniel A. Gamache

The entities that hold a legal rights for patent applications filed by inventor Gamache Daniel A.:

Recent patent applications by Gamache Daniel A.

Daniel A. Gamache from Arlington, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2019-01-31
US20190032061A1
Chemistry; metallurgy

RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions

#2 | 2017-03-16
US20170071895A1
Human necessities

High Concentration Olopatadine Ophthalmic Composition

#3 | 2017-02-23
US20170051291A1
Chemistry; metallurgy

RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders

#4 | 2016-12-22
US20160369283A1
Chemistry; metallurgy

RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions

#5 | 2016-09-08
US20160257963A1
Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF SPLEEN TYROSINE KINASE-RELATED INFLAMMATORY CONDITIONS

#6 | 2016-02-25
US20160053270A1
Chemistry; metallurgy

RNAi-mediated inhibition of histamine receptor H1-related conditions

#7 | 2014-12-04
US20140357695A1
Chemistry; metallurgy

RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

#8 | 2014-12-04
US20140357694A1
Chemistry; metallurgy

RNAi-mediated inhibition of tumor necrosis factor α-related conditions

#9 | 2014-10-02
US20140296328A1
Human necessities

High concentration olopatadine ophthalmic composition

#10 | 2014-08-14
US20140228430A1
Chemistry; metallurgy

Method of Accelerating Corneal Wound Healing

#11 | 2014-06-19
US20140171487A1
Chemistry; metallurgy

RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders

#12 | 2014-03-27
US20140088172A1
Chemistry; metallurgy

RNAi-mediated inhibition of histamine receptor H1-related conditions

#13 | 2014-03-18
US12580663
-

RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders

#14 | 2013-12-19
US20130338213A1
Human necessities

RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS

#15 | 2013-02-21
US20130045975A1
Human necessities

BICYCLIC HETEROARYL INHIBITORS OF PDE4

#16 | 2012-11-22
US20120295967A1
Human necessities

High concentration olopatadine ophthalmic composition

#17 | 2012-10-18
US20120264809A1
Chemistry; metallurgy

RNAi-mediated inhibition of histamine receptor H1-related conditions

#18 | 2012-03-15
US20120065187A1
Chemistry; metallurgy

HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE

#19 | 2012-01-19
US20120015953A1
Human necessities

METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALLERGY

#20 | 2011-11-24
US20110288157A1
Chemistry; metallurgy

RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

#21 | 2011-11-03
US20110269822A1
Chemistry; metallurgy

RNAi-mediated inhibition of histamine receptor H1-related conditions

#22 | 2011-08-25
US20110207809A1
Chemistry; metallurgy

METHOD OF ACCELERATING CORNEAL WOUND HEALING

#23 | 2011-06-16
US20110142767A1
Chemistry; metallurgy

RNAi-mediated inhibition of tumor necrosis factor α-related conditions

#24 | 2011-06-02
US20110130451A1
Human necessities

METHOD OF TREATING DRY EYE DISORDERS AND UVEITIS

#25 | 2010-05-13
US20100120741A1
Chemistry; metallurgy

HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE

#26 | 2010-04-01
US20100081646A1
Human necessities

Heteroarylalkoxy-substituted quinolone inhibitors of PDE4

#27 | 2010-03-11
US20100063047A1
Chemistry; metallurgy

AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE

#28 | 2009-12-31
US20090324507A1
Chemistry; metallurgy

RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

#29 | 2009-11-05
US20090274631A1
Chemistry; metallurgy

RNAi-mediated inhibition of histamine receptor H1-related conditions

#30 | 2009-07-16
US20090182035A1
Human necessities

USE OF A COMBINATION OF OLOPATADINE AND CILOMILAST TO TREAT NON-INFECTIOUS RHINITIS AND ALLERGIC CONJUNCTIVITIS

#31 | 2009-05-21
US20090131449A1
Human necessities

USE OF TRPV1 RECEPTOR ANTAGONISTS FOR TREATING DRY EYE AND OCULAR PAIN

#32 | 2009-04-16
US20090098136A1
Chemistry; metallurgy

USE OF TNF RECEPTOR ANTAGONISTS FOR TREATING DRY EYE

#33 | 2008-10-16
US20080254029A1
Human necessities

Use of an Inhibitor of TNFa Plus an Antihistamine to Treat Allergic Rhinitis and Allergic Conjunctivitis

#34 | 2008-06-12
US20080139531A1
Human necessities

USE OF CONNECTIVE TISSUE MAST CELL STABILIZERS TO FACILITATE OCULAR SURFACE RE-EPITHELIZATION AND WOUND REPAIR

#35 | 2008-04-24
US20080096852A1
Human necessities

USE OF OCULOSURFACE SELECTIVE GLUCOCORTICOID IN THE TREATMENT OF DRY EYE

#36 | 2007-12-06
US20070281901A1
Chemistry; metallurgy

RNAI-mediated inhibition of tumor necrosis factor α-related conditions

#37 | 2006-09-28
US20060217325A1
Human necessities

Treatment of dry eye restoring 15-lipoxygenase activity to ocular surface cells

#38 | 2006-08-24
US20060189541A1
Human necessities

Methods of treating dry eye disorders

#39 | 2006-06-15
US20060128803A1
Human necessities

Method of treating dry eye disorders using 13(S)-HODE and its analogs

#40 | 2006-05-11
US20060099248A1
Human necessities

5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses

#41 | 2006-04-11
US10650006
-

Methods of treating dry eye disorders

#42 | 2006-03-30
US20060069075A1
Human necessities

Methods for treating dry eye

#43 | 2006-03-16
US20060058375A1
Human necessities

Method of treating dry eye disorders and uveitis

#44 | 2006-03-16
US20060058277A1
Human necessities

Use of oculosurface selective glucocorticoid in the treatment of dry eye

#45 | 2006-01-19
US20060014782A1
Human necessities

Use of pde iv inhibitors to treat angiogenesis

#46 | 2005-12-15
US20050277648A1
Human necessities

Use of PDE IV inhibitors to treat angiogenesis

#47 | 2005-11-17
US20050256189A1
Human necessities

Method of treating dry eye disorders and uveitis

#48 | 2005-06-30
US20050143468A1
Human necessities

Method of treating vascular endothelial growth factor mediated vascular disorders

#49 | 2005-03-29
US10150193
-

Use of selective PDE IV inhibitors to treat dry eye disorders

InventorID:

102166 ⎘